{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:26:42Z","timestamp":1786678002250,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006416","name":"Universidade Estadual De Campinas","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006416","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The effects of gliflozins on bones of CKD patients on dialysis are unknown. Recently, SGLT2 expression in bone tissue of patients with CKD has been reported. We hypothesized that dapagliflozin may act in bone cells and modulate the Klotho-FGF23 axis. This study analyzed the effects of dapagliflozin on serum bone biomarkers and related outcomes. In this predefined post-hoc analysis of a previous RCT, patients on dialysis received (1:1) dapagliflozin 10\u00a0mg daily or standard care for 24\u00a0weeks. The primary endpoint was the change from baseline in serum Klotho and FGF23 levels, compared by ranked analysis of covariance, adjusted by baseline. Exploratory analyses evaluated calcium, phosphate, PTH, bone-ALP, TRAP-5b, DKK1, sclerostin, and bone proteins. Bone fractures, osteopenia, and osteoporosis were outcomes of interest. Seventy-nine patients were included in this analysis (Control N=40 and Dapagliflozin N=39). At baseline, no significant differences in biomarkers were observed. The prevalence of osteopenia and osteoporosis was 73% and 43% (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.60 and\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20091.00), respectively. After 24\u00a0weeks, the between-group analysis of the change from baseline (delta), adjusted by baseline, revealed a significant difference in serum Klotho [19.1 (\u2212\u200938.9\u201386.3) pg\/mL, Control group; \u2212\u200929.1 (\u2212\u200994.1\u201343.9) pg\/mL, Dapagliflozin group (F:4.946,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03)], but not on FGF23 levels, nor other biomarkers. The follow-up prevalences of osteopenia and osteoporosis were 70% and 48% (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.27 and\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.61, respectively). No bone fractures were observed. Dapagliflozin use over 24\u00a0weeks in patients on dialysis was independently associated with lowered serum Klotho levels, without effects in other bone biomarkers or related outcomes.\n                  <\/jats:p>","DOI":"10.1007\/s00223-026-01587-7","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:27:00Z","timestamp":1786674420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8365-8267","authenticated-orcid":false,"given":"Lauter E.","family":"Pelepenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-316X","authenticated-orcid":false,"given":"Joaquim","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9982-2260","authenticated-orcid":false,"given":"Mar\u00edlia P.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0093-0784","authenticated-orcid":false,"given":"Pedro B.","family":"Chiteculo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5900-0302","authenticated-orcid":false,"given":"Mariana C.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0216-7766","authenticated-orcid":false,"given":"Eric A.","family":"Corr\u00eaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4685-6990","authenticated-orcid":false,"given":"Mauro","family":"Pascoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2991-7678","authenticated-orcid":false,"given":"Gil","family":"Guerra-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3462-1860","authenticated-orcid":false,"given":"Wagner Vasques","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2786-9200","authenticated-orcid":false,"given":"Cinthia E. M.","family":"Carbonara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-7070","authenticated-orcid":false,"given":"Lo\u00efc","family":"Louvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7902-2127","authenticated-orcid":false,"given":"Rosa M. A.","family":"Moyses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0018-7269","authenticated-orcid":false,"given":"Makoto","family":"Kuro-O","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7127-2052","authenticated-orcid":false,"given":"Andrei C.","family":"Sposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8273-6200","authenticated-orcid":false,"given":"Rodrigo Bueno","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"1587_CR1","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"1587_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"1587_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"1587_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","volume":"143","author":"F Zannad","year":"2021","unstructured":"Zannad F, Ferreira JP, Pocock SJ et al (2021) Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation 143:310\u2013321. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051685","journal-title":"Circulation"},{"key":"1587_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"1587_CR6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"1587_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jchf.2020.04.008","volume":"8","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, Jhund PS, Claggett BL et al (2020) Effect of dapagliflozin in patients with HFrEF treated with sacubitril\/valsartan: the DAPA-HF trial. JACC Heart Fail 8:811\u2013818. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.008","journal-title":"JACC Heart Fail"},{"key":"1587_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"1587_CR9","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","volume":"142","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Cannon CP, Cherney DZI et al (2020) Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation 142:2205\u20132215. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050255","journal-title":"Circulation"},{"key":"1587_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J et al (2021) Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation 143:326\u2013336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051783","journal-title":"Circulation"},{"key":"1587_CR11","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","volume":"144","author":"M Packer","year":"2021","unstructured":"Packer M, Butler J, Zannad F et al (2021) Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation 144:1284\u20131294. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056824","journal-title":"Circulation"},{"key":"1587_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N et al (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:22\u201331. https:\/\/doi.org\/10.1016\/S2213-8587(20)30369-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1587_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cca.2019.11.040","volume":"502","author":"RB de Oliveira","year":"2020","unstructured":"de Oliveira RB, Stinghen AEM, Massy ZA (2020) Vitamin K role in mineral and bone disorder of chronic kidney disease. Clin Chim Acta 502:66\u201372. https:\/\/doi.org\/10.1016\/j.cca.2019.11.040","journal-title":"Clin Chim Acta"},{"key":"1587_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11914-022-00716-z","volume":"20","author":"M Fusaro","year":"2022","unstructured":"Fusaro M, Tondolo F, Gasperoni L et al (2022) The role of vitamin K in CKD-MBD. Curr Osteoporos Rep 20:65\u201377. https:\/\/doi.org\/10.1007\/s11914-022-00716-z","journal-title":"Curr Osteoporos Rep"},{"key":"1587_CR15","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:962\u2013971. https:\/\/doi.org\/10.1038\/ki.2013.356","journal-title":"Kidney Int"},{"key":"1587_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, Bilezikian JP, Usiskin K et al (2016) Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 101:157\u2013166. https:\/\/doi.org\/10.1210\/jc.2015-3167","journal-title":"J Clin Endocrinol Metab"},{"key":"1587_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-018-0028-0","volume":"14","author":"JE Blau","year":"2018","unstructured":"Blau JE, Taylor SI (2018) Adverse effects of SGLT2 inhibitors on bone health. Nat Rev Nephrol 14:473\u2013474. https:\/\/doi.org\/10.1038\/s41581-018-0028-0","journal-title":"Nat Rev Nephrol"},{"key":"1587_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","volume":"3","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI (2015) Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 3:8\u201310. https:\/\/doi.org\/10.1016\/S2213-8587(14)70227-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1587_CR19","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"1587_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/joneph\/aajag035","author":"MC de Oliveira","year":"2026","unstructured":"de Oliveira MC, Rufino L, Louren\u00e7o ALM et al (2026) Effects of gliflozins on bone in patients with chronic kidney disease: a systematic review. J Nephrol. https:\/\/doi.org\/10.1093\/joneph\/aajag035","journal-title":"J Nephrol"},{"key":"1587_CR21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/ndt\/gfaf256","volume":"41","author":"M Fusaro","year":"2026","unstructured":"Fusaro M, Chandran M, Nickolas T et al (2026) A consensus statement on the management of vertebral fractures in CKD stages G4\u2013G5D. Nephrol Dial Transplant 41:584\u2013598. https:\/\/doi.org\/10.1093\/ndt\/gfaf256","journal-title":"Nephrol Dial Transplant"},{"key":"1587_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/ki.2008.264","volume":"74","author":"TL Nickolas","year":"2008","unstructured":"Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721\u2013731. https:\/\/doi.org\/10.1038\/ki.2008.264","journal-title":"Kidney Int"},{"key":"1587_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4248\/BR201303001","volume":"1","author":"M Marenzana","year":"2013","unstructured":"Marenzana M, Arnett TR (2013) The key role of the blood supply to bone. Bone Res 1:203\u2013215. https:\/\/doi.org\/10.4248\/BR201303001","journal-title":"Bone Res"},{"key":"1587_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D et al (2021) The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol 20:150. https:\/\/doi.org\/10.1186\/s12933-021-01346-y","journal-title":"Cardiovasc Diabetol"},{"key":"1587_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41569-023-00903-0","volume":"21","author":"D Edmonston","year":"2024","unstructured":"Edmonston D, Grabner A, Wolf M (2024) FGF23 and klotho at the intersection of kidney and cardiovascular disease. Nat Rev Cardiol 21:11\u201324. https:\/\/doi.org\/10.1038\/s41569-023-00903-0","journal-title":"Nat Rev Cardiol"},{"key":"1587_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1570161118666200420102100","volume":"19","author":"E Memmos","year":"2021","unstructured":"Memmos E, Papagianni A (2021) New insights into the role of FGF-23 and klotho in cardiovascular disease in chronic kidney disease patients. Curr Vasc Pharmacol 19:55\u201362. https:\/\/doi.org\/10.2174\/1570161118666200420102100","journal-title":"Curr Vasc Pharmacol"},{"key":"1587_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117641","volume":"245","author":"SM Elshazly","year":"2026","unstructured":"Elshazly SM, Mahmoud NM, Ahmed GA et al (2026) Empagliflozin beyond antidiabetic effect: amelioration of cyclophosphamide-induced testicular toxicity in rats: orchestrating klotho\/Nrf-2\/PPAR-\u03b3\/NF-\u03baB\/Bax\/Bcl-2 cues. Biochem Pharmacol 245:117641. https:\/\/doi.org\/10.1016\/j.bcp.2025.117641","journal-title":"Biochem Pharmacol"},{"key":"1587_CR28","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.drudis.2021.04.007","volume":"26","author":"A Kale","year":"2021","unstructured":"Kale A, Sankrityayan H, Anders H-J, Bhanudas Gaikwad A (2021) Klotho: a possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes. Drug Discov Today 26:1963\u20131971. https:\/\/doi.org\/10.1016\/j.drudis.2021.04.007","journal-title":"Drug Discov Today"},{"key":"1587_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113677","volume":"154","author":"C Mora-Fern\u00e1ndez","year":"2022","unstructured":"Mora-Fern\u00e1ndez C, S\u00e1nchez-Ni\u00f1o MD, Donate-Correa J et al (2022) Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: a clinical and experimental study. Biomed Pharmacother 154:113677. https:\/\/doi.org\/10.1016\/j.biopha.2022.113677","journal-title":"Biomed Pharmacother"},{"key":"1587_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-026-01498-7","author":"LE Pelepenko","year":"2026","unstructured":"Pelepenko LE, dos Reis LM, Furukawa LNS, de Oliveira RB (2026) Bone from healthy individuals and patients with CKD expresses the sodium glucose co-transporter-2 (SGLT2). Calcif Tissue Int. https:\/\/doi.org\/10.1007\/s00223-026-01498-7","journal-title":"Calcif Tissue Int"},{"key":"1587_CR31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2215\/CJN.0000000000000196","volume":"18","author":"J Barreto","year":"2023","unstructured":"Barreto J, Borges C, Rodrigues TB et al (2023) Pharmacokinetic properties of Dapagliflozin in hemodialysis and peritoneal dialysis patients. Clin J Am Soc Nephrol 18:1051\u20131058. https:\/\/doi.org\/10.2215\/CJN.0000000000000196","journal-title":"Clin J Am Soc Nephrol"},{"key":"1587_CR32","unstructured":"Barreto J, Sposito AC et al. (2026) Cardiovascular effects of dapagliflozin in patients on chronic dialysis: The DARE-ESKD-2 Trial. Kidney Int Reports (in press)"},{"key":"1587_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237260","author":"C Cipriani","year":"2023","unstructured":"Cipriani C, Lauriero G, Tripepi G et al (2023) Effect of antidiabetic drugs on bone health in patients with normal renal function and in chronic kidney disease (CKD): insight into clinical challenges in the treatment of type 2 diabetes. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12237260","journal-title":"J Clin Med"},{"key":"1587_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2412228","author":"J Barreto","year":"2024","unstructured":"Barreto J, Martins M, Pascoa M et al (2024) (2024) Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2024.2412228","journal-title":"Expert Opin Drug Saf"},{"key":"1587_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99123","author":"JE Blau","year":"2018","unstructured":"Blau JE, Bauman V, Conway EM et al (2018) Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study. JCI insight. https:\/\/doi.org\/10.1172\/jci.insight.99123","journal-title":"JCI insight"},{"key":"1587_CR36","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1080\/03007995.2016.1174841","volume":"32","author":"M Alba","year":"2016","unstructured":"Alba M, Xie J, Fung A, Desai M (2016) The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin 32:1375\u20131385. https:\/\/doi.org\/10.1080\/03007995.2016.1174841","journal-title":"Curr Med Res Opin"},{"key":"1587_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Watts NB, Usiskin K et al (2016) Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 101:44\u201351. https:\/\/doi.org\/10.1210\/jc.2015-1860","journal-title":"J Clin Endocrinol Metab"},{"key":"1587_CR38","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00210-018-1544-y","volume":"391","author":"NAT Abbas","year":"2018","unstructured":"Abbas NAT, El Salem A, Awad MM (2018) Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression. Naunyn Schmiedebergs Arch Pharmacol 391:1347\u20131360. https:\/\/doi.org\/10.1007\/s00210-018-1544-y","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1587_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.kint.2017.02.014","volume":"92","author":"H Komaba","year":"2017","unstructured":"Komaba H, Kaludjerovic J, Hu DZ et al (2017) Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney Int 92:599\u2013611. https:\/\/doi.org\/10.1016\/j.kint.2017.02.014","journal-title":"Kidney Int"},{"key":"1587_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1469-7580.2008.00859.x","volume":"212","author":"H Suzuki","year":"2008","unstructured":"Suzuki H, Amizuka N, Oda K et al (2008) Histological and elemental analyses of impaired bone mineralization in klotho-deficient mice. J Anat 212:275\u2013285. https:\/\/doi.org\/10.1111\/j.1469-7580.2008.00859.x","journal-title":"J Anat"},{"key":"1587_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bone.2013.08.008","volume":"57","author":"M Sasaki","year":"2013","unstructured":"Sasaki M, Hasegawa T, Yamada T et al (2013) Altered distribution of bone matrix proteins and defective bone mineralization in klotho-deficient mice. Bone 57:206\u2013219. https:\/\/doi.org\/10.1016\/j.bone.2013.08.008","journal-title":"Bone"},{"key":"1587_CR42","doi-asserted-by":"publisher","first-page":"R93","DOI":"10.1530\/EC-20-0039","volume":"9","author":"M Cohen-Solal","year":"2020","unstructured":"Cohen-Solal M, Funck-Brentano T, Ure\u00f1a Torres P (2020) Bone fragility in patients with chronic kidney disease. Endocr Connect 9:R93\u2013R101. https:\/\/doi.org\/10.1530\/EC-20-0039","journal-title":"Endocr Connect"},{"key":"1587_CR43","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s11357-023-00803-8","volume":"45","author":"G Yildirim","year":"2023","unstructured":"Yildirim G, Bergamo ETP, Poudel SB et al (2023) Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice. GeroScience 45:1933\u20131951. https:\/\/doi.org\/10.1007\/s11357-023-00803-8","journal-title":"GeroScience"},{"key":"1587_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae128","volume":"8","author":"C Chlebek","year":"2024","unstructured":"Chlebek C, McAndrews C, Costa SN et al (2024) In nondiabetic C57BL\/6J mice, canagliflozin affects the skeleton in a sex- and age-dependent manner. JBMR Plus 8:ziae128. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae128","journal-title":"JBMR Plus"},{"key":"1587_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1081039","volume":"13","author":"P Song","year":"2022","unstructured":"Song P, Chen T, Rui S et al (2022) Canagliflozin promotes osteoblastic MC3T3-E1 differentiation via AMPK\/RUNX2 and improves bone microarchitecture in type 2 diabetic mice. Front Endocrinol 13:1081039. https:\/\/doi.org\/10.3389\/fendo.2022.1081039","journal-title":"Front Endocrinol"},{"key":"1587_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13040246","author":"S Magnani","year":"2021","unstructured":"Magnani S, Atti M (2021) Uremic toxins and blood purification: a review of current evidence and future perspectives. Toxins. https:\/\/doi.org\/10.3390\/toxins13040246","journal-title":"Toxins"},{"key":"1587_CR47","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/ki.2011.445","volume":"81","author":"C-Y Sun","year":"2012","unstructured":"Sun C-Y, Chang S-C, Wu M-S (2012) Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 81:640\u2013650. https:\/\/doi.org\/10.1038\/ki.2011.445","journal-title":"Kidney Int"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01587-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01587-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01587-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:27:03Z","timestamp":1786674423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01587-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1587"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01587-7","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest related to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board approved each enrolled site before the study initiation, and all participants signed an informed consent form.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was registered at Clinicaltrials.gov (NCT05685394) before recruitment.","order":3,"name":"Ethics","label":"Research Involving Human Participants","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"130"}}